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Abstract
Introduction Statins may theoretically reduce postoperative
atrial fibrillation (AF) in patients after cardiac valvular
surgery due to preservation of endothelial function and anti-
ischaemic, anti-inflammatory and anti-remodelling effects.
Methods Two hundred seventy-two patients who under-
went cardiac workup and subsequently cardiac valvular
surgery without AF and concomitant coronary artery
bypass grafting (CABG) at our hospital were selected.
Preoperative drug use and postoperative AF were recorded.
AF was defined as any episode of AF longer than 10 s. In
addition, results from echocardiography and blood samples
were retrieved.
Results Baseline characteristics were as follows: mean age
was 65±11 years, 142 (52%) patients were male, 189 (70%)
had undergone aortic valve surgery and the mean left
ventricular ejection fraction was 57±12%. Statins were used
by 79 patients (29%). Statin users, more often, had a prior
percutaneous coronary intervention (25% vs 9%, p<0.001) or
CABG (24% vs 4%, p<0.001), diabetes mellitus (22% vs
5%, p<0.001) and more often used β-blockers (51% vs 24%,
p<0.001). Patients in the non-statin group more often had
surgery on more than one valve (10% vs 3%, p=0.043) and
had a higher cholesterol level (222±48 vs 190±43 mg/dl,
p<0.001). Postoperative AF occurred in 54% (43/79) of the
patients with and in 55% (106/193) of the patients without
statins (p=0.941). There was also no difference in the timing
of onset of AF or duration of hospital stay.
Conclusion In this observational study, statin use was not
associated with a reduced incidence of AF in patients after
cardiac valvular surgery.
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Introduction
Cardiac valvular surgery has excellent long-term survival
results and is the treatment of choice in patients with severe
valvular disease [1]; however, postsurgical morbidity
remains high. Frequent complications such as atrial
fibrillation (AF) may worsen prognosis, prolong hospital
stay and increase medical costs. Therefore, it is important to
improve strategies to reduce postsurgical morbidity. In this
respect, statins are interesting drugs. Statins have shown to
reduce morbidity and mortality in a broad range of patients
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DOI 10.1007/s12471-010-0055-3with cardiovascular diseases [2, 3]. In addition to
cholesterol-lowering properties, experimental and clinical
data suggest that statins may also exhibit anti-
inflammatory, endothelial protective, antioxidative and
anti-remodelling effects [4–8]. Indeed, statins may prevent
AF after coronary artery bypass grafting (CABG) surgery
[9, 10]; however, this does not prove a pleiotropic effect
since this may be caused by the vasoprotective effects of
statins and reduction of ischaemia, thereby preventing AF.
Ischaemia due to coronary artery disease is less likely to
play a major role after valvular surgery; however, few data
exist on the possible protective effects of statins after
cardiac valvular surgery. Therefore, we hypothesise that




In retrospect, 272 consecutive patients undergoing cardi-
ac valvular surgery in our department between July 1996
and March 2004 were identified. Patients with AF on the
day of surgery or with concomitant CABG were
excluded to avoid treatment bias due to symptomatic
coronary artery disease. Patients referred from other
hospitals were excluded because of incomplete pre- and
postoperative data for this observational study. After
these exclusions, our study cohort consisted of 272
patients who underwent cardiac valvular surgery without
concomitant CABG in our hospital during this period.
Patients with prior cardiac surgery, including CABG,
were not excluded.
Data Collection
Echocardiographic data were collected from our routine
clinical database. In addition, admission levels of
haemoglobin and creatinine were retrieved as well as
the maximal creatinine phosphokinase in the first 24 h
after surgery.
Each medical chart was reviewed for preoperative
medication, including statins, β-adrenergic receptor block-
ers, angiotensin-converting enzyme inhibitors, angiotensin
II receptor blockers and antiarrhythmic drugs. These drugs
needed to be prescribed for at least 1 week prior to surgery
if a drug was considered to be given.
Atrial Fibrillation
AF was defined as any episode of AF longer than 10 s.
Rhythm data during admission were attained by retrieving
all electrocardiographic and Holter recordings from the
medical chart. Data on previous episodes of AF were
attained from the chart and from our clinical ECG database.
Statistical Analysis
All statistics were performed by SPSS version 11.0. Results
are presented as the mean value ±SD for continuous
variables and as the percentage of total patients for
categorical data. The independent samples t test was used
for comparison of continuous variables and the χ
2 test for
categorical variables. Potential predictors of hospital stay
were related to the duration of stay in days using linear
regression analysis. For this purpose, the duration was log-
normalised since it was skewed.
Cholesterol levels were missing in 41 (15%) patients.
Therefore, we first assessed whether the missing status was
statistically informative using a dummy variable. Since this
was not the case, the missing values were imputed using
‘the mean value of the whole group’ approach. Multivar-
iable logistic regression was performed to test whether
statin prescription was associated with postoperative AF
occurrence when correcting for potential confounders.
Variables entered in the model were age, sex, New York
Heart Association class, previous AF, history of percutane-
ous coronary interventions (PCI), history of CABG, prior
valvular surgery, pulmonary hypertension, haemoglobin
level, atrial size, the use of β-blockers, antiarrhythmic
drugs, aortic valve surgery, combined surgery on more than
one valve and the use of statin and the propensity score.
The effect of statin prescription on occurrence of postop-
erative AF might be biased by the absence of randomisation
in this observational study, and therefore a propensity score
was added to the multivariate logistic regression model in
order to correct as well as possible for the propensity of a
physician to select patients for prescribing statins. Individ-
ual propensity scores were calculated by means of
backward deletion logistic regression (see “Methods”).
The propensity score was added as a continuous variable
to the multivariable logistic regression analysis. The
variable for statin prescription and its propensity score
were kept at all times in the model regardless of their
significance, since this was the main effect we wanted to
test.
Results
The mean age of the patients was 65±11 years, the mean
left ventricular ejection fraction was 57±12%, 142 patients
(52%) were male and 20% had a history of AF (Table 1).
Aortic valve replacement was performed in 189 (70%)
18 Neth Heart J (2011) 19:17–23patients, mitral valve repair or replacement in 78 (29%)
patients and 21 (8%) patients had surgery on more than one
valve. A total of 201 (75%) patients received a mechanical
valve. Table 1 shows the baseline characteristics and a
comparison of statin vs non-statin users.
Statin users more often had diabetes mellitus (22% vs
5%, p<0.001) and more often used β-blockers (51% vs
24%, p<0.001). In addition, these patients more often had a
history of PCI (25% vs 9%, p<0.001) or CABG (24% vs
4%, p<0.001). Patients in the non-statin group more often
had surgery on more than one valve (10% vs 3%, p=
0.043), and a higher cholesterol level (222±48 vs 190±
43 mg/dl, p<0.001).
Statin Use and Postoperative Atrial Fibrillation
AF occurred after a mean of 4.0±3.7 days in patients
without and after 3.7±3.3 days in patients with a statin (p=
0.615). Table 2 shows the univariate differences in
characteristics between patients who had postoperative AF
vs the ones without AF. Patients with postoperative AF
were older and more often male. In addition, they more
often had a history of PCI or pulmonary hypertension, had
a lower haemoglobin level, a larger left atrium, more often
used an antiarrhythmic drug and were more often operated
on more than one valve. AF occurred in 149/272 (55%) of
the patients undergoing surgery in sinus rhythm. Forty-
All Statin users Non-statin users P
N=272 N=79 N=193
Age (years) 65±11 65±11 65±11 0.510
Male (%) 142 (52) 41 (52) 101 (52) 0.948
Previous history, n (%)
NYHA I 37 (14) 8 (11) 29 (15)
NYHA II 55 (21) 16 (22) 39 (21)
NYHA III 146 (56) 41 (56) 105 (56)
NYHA IV 23 (9) 8 (11) 15 (8) 0.728
AF 54 (20) 17 (22) 37 (19) 0.659
PCI 37 (14) 20 (25) 17 (9) <0.001
CABG 26 (10) 19 (24) 7 (4) <0.001
Valve surgery 23 (9) 10 (13) 13 (7) 0.111
Diabetes 27 (10) 17 (22) 10 (5) <0.001
COPD 31 (12) 8 (11) 23 (12) 0.743
Hypertension 110 (40) 37 (47) 73 (38) 0.169
Pulmonary hypertension 107 (41) 30 (39) 77 (42) 0.641
Laboratory
Haemoglobin (mmol/l) 8.4±1.0 8.4±1.0 8.4±1.0 0.741





Cholesterol (mg/dl) 212±49 190±43 222±48 <0.001
Echocardiography
Left atrial size (mm) 48±8 49±7 48±8 0.894
LVEF (%) 57±12 56±11 58±12 0.349
Drugs, n (%)
ACE-I 127 (47) 41 (52) 86 (45) 0.271
Beta-blocker 87 (32) 40 (51) 47 (24) <0.001
AAD 44 (16) 12 (15) 32 (17) 0.777
Surgery, n (%)
Emergency 12 (4) 3 (4) 9 (5) 0.752
Aortic valve 189 (70) 57 (72) 132 (68) 0.541
Mitral valve 78 (29) 19 (24) 59 (31) 0.280
>1 valve 21 (8) 2 (3) 19 (10) 0.043
Mechanical prosthesis 201 (75) 62 (81) 139 (72) 0.166
ECC time (min) 105±42 102±35 106±45 0.430
ACC time (min) 75±29 70±22 77±31 0.075
Table 1 Baseline characteristics
and comparison between statin
users and non-statin users
NYHA New York Heart Associ-
ation, COPD chronic obstructive
pulmonary disease, ACE-I
angiotensin-converting enzyme
inhibitor or angiotensin II re-
ceptor blocker, AAD class I or
III antiarrhythmic drugs, ECC
extracorporal circulation clamp
time, ACC aorta circulation
clamp, LVEF left ventricular
ejection fraction
a25th and 75th percentiles
bMann–Whitney U results
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compared with 106/193 (55%) patients not taking these
cholesterol-lowering drugs (p=0.941). The incidence of AF
in patients without any previous episode of AF was 49% in
non-statin users vs 50% in statin users, (p=0.864).
In the multivariate analysis, statin use was not associated
with AF occurrence (p=0.345). Significant predictors of
postoperative AF were age, a previous episode of AF, a
history of CABG and pulmonary hypertension (Table 3).
The mean propensity score for statin use was 0.27 (25th
and 75th percentiles, 0.05 and 0.42, respectively).
No AF AF P
N=123 N=149
Age (years) 63±12 67±10 0.002
Male, n (%) 48 (39) 82 (55) 0.009
Previous history, n (%)
NYHA I 24 (21)
a 13 (9)
NYHA II 20 (17) 35 (24)
NYHA III 64 (55) 82 (57)
NYHA IV 9 (8) 14 (10) 0.047
AF 12 (10) 42 (28) <0.001
PCI 19 (15) 12 (8) 0.056
CABG 16 (13) 10 (7) 0.079
Valve surgery 29 (10) 11 (13) 0.198
Diabetes 10 (8) 17 (11) 0.368
COPD 17 (14) 14 (10) 0.219
Hypertension 47 (38) 63 (42) 0.496
Pulmonary hypertension 36 (32) 71 (49) 0.006
Laboratory
Haemoglobin (mmol/l) 8.6±0.9 8.3±1.1 0.019




Cholesterol (mg/dl) 211±51 212±47 0.781
Echocardiography
Left atrial size (mm) 47±8 49±3 0.048
LVEF (%) 57±13 57±11 0.824
Drugs, n (%)
ACE-I 53 (43) 74 (50) 0.279
Beta-blocker 33 (27) 54 (36) 0.098
Statin 36 (29) 43 (29) 0.941
AAD 13 (11) 31 (21) 0.023
Surgery, n (%)
Emergency 7 (6) 5 (3) 0.351
Aortic valve 92 (75) 97 (65) 0.084
Mitral valve 32 (26) 46 (31) 0.378
>1 valve 5 (4) 16 (11) 0.037
Mechanical prosthesis 95 (77) 106 (73) 0.384
ECC time (min) 103±43 106±41 0.554
ACC time (min) 74±30 76±28 0.668
Table 2 Comparison of patients
with and without AF
NYHA New York Heart Associ-
ation, COPD chronic obstructive
pulmonary disease, ACE-I
angiotensin-converting enzyme
inhibitor or angiotensin II re-
ceptor blocker, AAD class I or
III antiarrhythmic drugs, ECC
extracorporal circulation clamp
time, ACC aorta circulation
clamp, LVEF left ventricular
ejection fraction
a25 and 75 percentiles
bMann–Whitney U results
Table 3 Multivariate analysis with propensity scores for statin
P value OR (95% CI)
Age 0.002 1.05 (1.017–1.074)
Previous AF 0.001 4.55 (1.905–10.856)
Previous CABG 0.029 0.24 (0.067–0.867)
Pulmonary hypertension 0.022 1.98 (1.102–3.557)
Statin 0.345 1.49 (0.651–3.403)
20 Neth Heart J (2011) 19:17–23Interactions were observed between statin and hae-
moglobin levels (p=0.024); however, statin therapy was
still not predictive of postoperative AF in patients with a
mean haemoglobin of ≤8.41 mmol/l (p=0.914) vs those
with levels >8.41 mmol/l (p=0.552). Other interactions
were noted between age and sex (p=0.013) and between
history of AF and surgery on more than one valve (p=
0.012).
Statin Use and Length of Hospital Stay and Mortality
The mean length of hospital stay was 13.9 days (25th and
75th percentiles, 7 and 18 days, respectively). The use of
statins was not associated with shorter hospitalisation, 4%
decrease in hospital stay duration, 95% CI −18±12% (p=
0.602). In-hospital mortality was 4% in both statin and non-
statin users (p=0.971).
Subgroup Analysis
The most powerful predictor of postoperative AF is a
history of AF. One may argue that if statins were not
able to prevent AF prior to surgery, they may also not
prevent AF after surgery. Therefore, another subanalysis
was performed in patients without a history of AF. By
excluding these, 218 (80%) patients remained in the
model, of which 62 (28%) used a statin and 107 (49%)
developed AF. Multivariate predictors of postsurgical AF
were age (p=0.015) and haemoglobin levels prior to
surgery (p=0.035). Still, the use of a statin was not
associated with AF (p=0.392).
Another subanalysis was performed in patients with-
out previous PCI or CABG, leaving a total of 226 (83%)
patients. In this subgroup, 52 (23%) used a statin and
124 patients (55%) developed AF. When excluding
patients with prior CABG, none of the patients under-
going prior valve surgery remained. Except for this, the
same variables as in the main model were entered in the
multivariate analysis, as all had univariate p values
<0.10. Multivariate predictors of postsurgical AF were
age (p=0.005) and prior AF (p=0.001). The use of statin
was not associated with AF (p=0.782). In this model,
pulmonary hypertension did not reach significance (p=
0.074).
Discussion
This study shows that treatment with statins is not
associated with a reduction of AF in patients undergoing
valvular surgery. In line with these observations, statins
were not associated with a shorter hospital stay.
Statins and Postoperative AF
Risk factors for atherosclerotic disease such as hypertension
and age are associated with an increased risk for AF. This
suggests an association between AF and atherosclerotic
vascular disease [11]. In contrary to most studies, we
excluded concomitant CABG surgery to minimise the effect
of atherosclerotic vascular disease. Thus far, several studies
after thoracic surgery have shown conflicting results. Four
observational studies in patients after CABG and non-
cardiac thoracic surgery have shown a decreased postoper-
ative AF incidence with the use of a statin [12–15]. In
addition, a randomised trial of 200 patients showed that in
patients after CABG surgery, AF was reduced by almost 40%
with atorvastatin starting 1 week before the operation (35%
vs 57%, p=0.003) [9]. This is in accordance with the finding
that statins may reduce AF in patients with symptomatic
coronary artery disease [10]. Such an effect seems plausible
since statins can prevent atherosclerosis and its consequences;
however, these data are in conflict with a large retrospective
cohort analysis in 4,044 patients in which statins were not
associated with AF reduction after CABG [16].
In concert with this, we found no relation between statin
treatment and postoperative AF in patients after valvular
surgery. Discrepancies between studies may relate to the
type of patients. It may be assumed that patients with
coronary artery disease respond better to statins than
patients undergoing valvular surgery. In addition, the severe
valvular disease has already led to a substrate for AF,
irrespective of the inflammatory effects caused by the
operation. This is illustrated by a higher incidence of AF
after valvular surgery compared with CABG surgery. In the
latter, postoperative AF is more likely to depend on excess
triggers caused by the inflammatory response to surgery.
Therefore, reduction of inflammation by statins may
decrease the incidence of AF in the CABG patients, but
not after valvular surgery.
Our patients may differ significantly from previous
studies since they had a high postoperative AF rate
suggesting significant remodelling and inflammation not
suppressible by statins.
Mechanisms by Which Statins May Prevent AF
Theoretically, statins may reduce postoperative AF by
several mechanisms. Firstly, statins may exert systemic
anti-inflammatory effects by reducing T cell activation,
thereby reducing inflammatory cytokine production such as
IL-6 and C-reactive protein (CRP) [17, 18]. A high CRP
level is a risk factor for cardiovascular events, including the
development and maintenance of AF [4, 19–21]. AF
incidence peaks 2–3 days after thoracic surgery when
Neth Heart J (2011) 19:17–23 21CRP levels are highest. In addition, higher CRP levels are
associated with higher AF burden [20]. Further evidence of
an inflammatory basis of AF is supported by atrial biopsies,
showing that atrial myocarditis is frequent in lone AF [21].
Inflammation may lead to AF by slowing atrial conduction,
thereby facilitating re-entry [22, 23].
Other reported beneficial effects of statins to prevent AF
are their antioxidant, anti-remodelling properties, modifica-
tion of neurohormonal activation of the renin–angiotensin
and the autonomic nervous system, direct antiarrhythmic
effects by cell membrane ion channel stabilisation, direct
protection of the ischaemic myocardium or modulation of
the extracellular matrix.
Study Limitations
We performed an observational study, so we did not
randomise our patients. This is reflected by the differences
in baseline characteristics. Although the statin group more
often had diabetes mellitus, the non-statin group more often
had surgery on more than one valve and a higher
cholesterol level; however, by adding propensity scores to
the multivariate analysis, we corrected as well as possible
for the differences between the statin and non-statin users.
In addition, the sample size may be too small for
drawing firm conclusions; however, no small trend in
favour of statin use was seen. In the univariate analysis, a
statin was used in 29% of patients with and without AF (p=
0.941 in univariate analysis). Therefore, it is unlikely that
sample size precluded significance, although it cannot be
excluded.
All patients in the statin group used a statin for at least
1 week. We did not analyse duration, dosing and the
different types of statins. Despite these drawbacks, our
study does not support the hypothesis that pleiotropic
effects of statins may decrease AF in this population.
Conclusion
Statins are not associated with a decreased incidence of
AF after cardiac valvular surgery. Our results conflict
with most reports in patients with vascular disease in
which statins may be beneficial. Further research should
focus on the role of statins in subjects who are not
vascularly compromised.
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